Candida Vitale

Dr. Candida Vitale

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
CVCandida Vitale
Candida Vitale
Paolo StratiPaolo Strati
Paolo Strati
Chimeric antigen receptor-modified (CAR) T cells targeting CD19 have revolutionized the treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has increased the cure rate for these cancers from 10 to 40%. Two second-generation anti-CD19 CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel, have been approved for use in patients, and the approval of a third product, lisocabtagene maraleucel, is expected in 2020. The commercial availability of the first two products has facilitated the development of real-world experience in treating relapsed or refractory aggressive B-cell lymphomas, shed light on anti-CD19 CAR T-cell products' feasibility in trial-ineligible patients, and raised the need for strategies to mitigate the adverse effects associated with anti-CD19 CAR T-cell therapy, such as cytokine release syndrome, neurotoxicity, and cytopenia. In addition, promising clinical data supporting the use of anti-CD19 CAR T-cell therapy in patients with indolent B-cell lymphomas or chronic lymphocytic leukemia have recently become available, breaking the paradigm that these conditions are not curable. Multiple clinical CAR T-cell therapy-based trials are ongoing. These include studies comparing CAR T-cell therapy to autologous stem cell transplantation or investigating their use at earlier stages of disease, novel combinations, and novel constructs. Here we provide a thorough review on the use of the anti-CD19 CAR T-cell products axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel in patients with indolent or aggressive B-cell lymphoma or with chronic lymphocytic leukemia, and present novel CAR T cell-based approaches currently under investigation in these disease settings.

1 November 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
AKAnargyros Kapetanakis
Anargyros Kapetanakis
LSLydia Scarfò
Lydia Scarfò
GKGeorgios Karakatsoulis
Georgios Karakatsoulis
David AllsupDavid Allsup
David Allsup
PGPaolo Prospero Ghia
Paolo Prospero Ghia
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

1 June 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
LFL. Falchi
L. Falchi
CVCandida Vitale
Candida Vitale
MKM. J. Keating
M. J. Keating
SLS. Lerner
S. Lerner
XWX. Wang
X. Wang
Alessandra FerrajoliAlessandra Ferrajoli
Alessandra Ferrajoli
Background Information on the impact of other cancers (OC) in long-term survivors (LTS) of chronic lymphocytic leukemia (CLL) is limited. Patients and methods Patients with CLL who survived >10 years were defined as LTS of CLL. We calculated standardized incidence ratios (SIR) to compare the incidence of OC in LTS of CLL vs. the general population. A multivariable model was used to identify independent predictors of OC. Overall survival was analyzed as a function of the presence of OC. Results Among 797 LTS of CLL, the cumulative frequency of OC was 36%, similar between 570 patients (72%) who required treatment for CLL (TRT) and 227 (28%) who remained untreated (UT). The most common OC in both groups was non-melanoma skin cancer, followed by prostate cancer, breast cancer, melanoma, lung cancer, and leukemia in TRT patients, and by prostate cancer, breast cancer, melanoma, lung cancer and gastrointestinal tumors in the UT group. The SIR for all OC was 1.2 (P=0.034). It was higher in males (SIR 1.31; P=0.013) and patients <60 years (SIR 1.27; P=0.027). A higher SIR was shown for secondary leukemia, melanoma and head and neck cancers, while a lower SIR was found for gastrointestinal and bladder cancers. Independent predictors of OC development were advanced age, male gender and lower platelets. The survival of patients with OC was 16.2 months and that of patients without OC 22.9 years. Conclusions LTS of CLL have an increased incidence of OC compared to the general population. CLL therapy is not a risk factor for OC in LTS of CLL. The presence of an OC in these patients may be associated with shorter survival.

18 October 2012 in Blood
Verified
Journal Article
Closed access
PDF file
Marta CosciaMarta Coscia
Marta Coscia
CVCandida Vitale
Candida Vitale
SPSilvia Peola
Silvia Peola
MFMyriam Foglietta
Myriam Foglietta
MRMicol Rigoni
Micol Rigoni
MMMassimo Massaia
Massimo Massaia
The role of Vγ9Vδ2 T cells in chronic lymphocytic leukemia (CLL) is unexplored, although these cells have a natural inclination to react against B-cell malignancies. Proliferation induced by zoledronic acid was used as a surrogate of γδ TCR-dependent stimulation to functionally interrogate Vγ9Vδ2 T cells in 106 untreated CLL patients. This assay permitted the identification of responder and low-responder (LR) patients. The LR status was associated with greater baseline counts of Vγ9Vδ2 T cells and to the expansion of the effector memory and terminally differentiated effector memory subsets. The tumor immunoglobulin heavy chain variable region was more frequently unmutated in CLL cells of LR patients, and the mevalonate pathway, which generates Vγ9Vδ2 TCR ligands, was more active in unmutated CLL cells. In addition, greater numbers of circulating regulatory T cells were detected in LR patients. In multivariate analysis, the LR condition was an independent predictor of shorter time-to-first treatment. Accordingly, the time-to-first treatment was significantly shorter in patients with greater baseline numbers of total Vγ9Vδ2 T cells and effector memory and terminally differentiated effector memory subpopulations. These results unveil a clinically relevant in vivo relationship between the mevalonate pathway activity of CLL cells and dys-functional Vγ9Vδ2 T cells.

14 September 2015 in OncoImmunology
Verified
Journal Article
Open access
BCBarbara Castella
Barbara Castella
MFMyriam Foglietta
Myriam Foglietta
PSPatrizia Sciancalepore
Patrizia Sciancalepore
MRMicol Rigoni
Micol Rigoni
Marta CosciaMarta Coscia
Marta Coscia
MMMassimo Massaia
Massimo Massaia
Vγ9Vδ2 T cells have a natural inclination to recognize malignant B cells in vitro via receptors for stress-induced self-ligands and TCR-dependent recognition of phosphoantigens (pAgs) generated in the mevalonate (Mev) pathway. This inclination is continuously challenged in vivo by the immune suppression operated by tumor cells. Multiple myeloma (MM) is a prototypic B-cell malignancy in which myeloma cells subvert the local microenvironment to reshape antitumor immune responses. In this study, we have investigated the immune competence of bone marrow (BM) Vγ9Vδ2 T cells in a large series of MM patients. We have found that the BM microenvironment significantly hampers the pAg-reactivity of BM Vγ9Vδ2 T cells, which become largely PD-1+ and are surrounded by PD-L1+ myeloma cells and increased numbers of PD-L1+ myeloid-derived suppressor cells (MDSC). Vγ9Vδ2 T-cell dysfunction is an early event that can be already detected in individuals with monoclonal gammopathy of undetermined significance (MGUS) and not fully reverted even when MM patients achieve clinical remission. Anti-PD-1 treatment increases the cytotoxic potential of Vγ9Vδ2 T cells by almost 5-fold after pAg stimulation, and appears to be a promising strategy for effective immune interventions in MM.

4 March 2011 in Leukemia
Verified
Journal Article
Closed access
Marta CosciaMarta Coscia
Marta Coscia
FPF Pantaleoni
F Pantaleoni
Chiara RigantiChiara Riganti
Chiara Riganti
CVCandida Vitale
Candida Vitale
MRM Rigoni
M Rigoni
MMMassimo Massaia
Massimo Massaia